Nifedipine    (DrugBank: Nifedipine)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
50皮膚筋炎/多発性筋炎1
81先天性副腎皮質酵素欠損症1

50. 皮膚筋炎/多発性筋炎 [臨床試験数:157,薬物数:207(DrugBank:76),標的遺伝子数:47,標的パスウェイ数:142
Searched query = "Dermatomyositis", "Polymyositis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 157 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03027674
(ClinicalTrials.gov)
August 201613/1/2017Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary RaynaudColor Doppler Ultrasound Comparison of Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud: A Randomized, Double-blind, Placebo-controlled Pilot StudyRaynaud Phenomenon Due to Trauma;Raynaud Disease;System; Sclerosis;Lupus Erythematosus, Systemic;Dermatomyositis;Ultrasound Therapy; ComplicationsDrug: 10% nifedipine cream;Drug: 5% sildenafil creamPontificia Universidad Catolica de ChileNULLCompleted13 Years99 YearsAll10Early Phase 1Chile

81. 先天性副腎皮質酵素欠損症 [臨床試験数:65,薬物数:77(DrugBank:20),標的遺伝子数:11,標的パスウェイ数:65
Searched query = "Congenital adrenal hyperplasia", "Congenital adrenal enzyme deficiency", "Congenial adrenal cortex enzyme deficiency", "Congenital Lipoid Adrenal Hyperplasia", "3β-Hydroxysteroid Dehydrogenase Deficiency", "21-Hydroxylase deficiency", "11β-Hydroxylase deficiency", "17α-Hydroxylase deficiency", "P450 oxidoreductase deficiency", "Aldosterone synthase deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 65 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00000102
(ClinicalTrials.gov)
3/11/1999Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic TargetsCongenital Adrenal HyperplasiaDrug: NifedipineNational Center for Research Resources (NCRR)NULLCompleted14 Years35 YearsBothPhase 1;Phase 2United States